PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 62012

Title: Update on the treatment of metastatic renal cell carcinoma

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05278701
Position: Editorial Board

Academic degree: MD

Professional title: Professor, Staff Physician

Reviewer’s Country/Territory: Brazil

Author’s Country/Territory: Spain

Manuscript submission date: 2020-12-25

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2021-09-03 12:35

Reviewer performed review: 2021-09-03 12:47

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review          | [ ] Yes                  | [Y] No                      |

| Peer-reviewer      | Peer-Review: [Y] Anonymous | [ ] Onymous |


SPECIFIC COMMENTS TO AUTHORS

I appreciate the opportunity to review the editorial by Medina et al. We suggest the Editor the publication of this manuscript.
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 62012

Title: Update on the treatment of metastatic renal cell carcinoma

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05566451

Position: Editorial Board

Academic degree: PhD

Professional title: Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Spain

Manuscript submission date: 2020-12-25

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2021-09-14 15:23

Reviewer performed review: 2021-09-19 11:51

Review time: 4 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Peer-reviewer: Peer-Review: Yes Anonymous
SPECIFIC COMMENTS TO AUTHORS

The manuscript reviews some questions regarding mRCC management, include head-to-head comparisons between the current options, treatment sequencing, non-clear cell mRCC, and the role of biomarkers to ascertain the best treatment choice. It has guiding significance to clinic.